Oct 9, 2024
Landmark Study Identifies Potential New Way To Treat Depression and Anxiety
Posted by Saúl Morales Rodriguéz in categories: innovation, neuroscience
Researchers highlight LXRβ as a potential target for treating depression, anxiety, and autism. While promising, further studies are needed to confirm its effectiveness in humans.
In a state-of-the-art Bench to Bedside review published in the journal Brain Medicine (Genomic Press), Dr. Xiaoyu Song from the University of Houston and Professor Jan-Åke Gustafsson from Sweden’s Karolinska Institute explore the therapeutic potential of liver X receptor beta (LXRβ) in treating depression and anxiety. Their comprehensive analysis represents a major advancement in understanding the molecular mechanisms underlying mental health disorders, with the potential to transform future treatment approaches.
LXRβ, a nuclear receptor initially known for its role in cholesterol metabolism and inflammation, is now emerging as a crucial player in neuroscience and psychiatry. The review synthesizes recent breakthroughs in understanding LXRβ’s regulation and function in behaviors relevant to depression and anxiety, derived from studies using animal models that capture specific features of these disorders.